Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Breast cancer facts.

[No authors listed]

J Okla State Med Assoc. 2012 Oct;105(10):411-2. No abstract available.

PMID:
23316677
2.

Moving forward with breast cancer prevention.

Chen WY, Rosner B, Colditz GA.

Cancer. 2007 Jun 15;109(12):2387-91. Review. No abstract available.

3.

Breast cancer risk reduction: what do we know and where should we go?

Prout MN.

Medscape Womens Health. 2000 Sep-Oct;5(5):E4. Review.

PMID:
11113777
4.

Chemoprevention of breast cancer.

Dalton RR, Kallab AM.

South Med J. 2001 Jan;94(1):7-15. Review.

PMID:
11213947
5.

Tamoxifen prevention of breast cancer: an instance of the fingerpost.

Lippman SM, Brown PH.

J Natl Cancer Inst. 1999 Nov 3;91(21):1809-19. Review. No abstract available.

PMID:
10547388
7.

Breast cancer chemoprevention: a review of selective estrogen receptor modulators.

Johansen AM.

Clin J Oncol Nurs. 2005 Jun;9(3):317-20. Review.

PMID:
15973842
8.

Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.

Ganz PA, Land SR.

Menopause. 2008 Jul-Aug;15(4 Suppl):797-803. doi: 10.1097/gme.0b013e31817be9af. Review.

PMID:
18596601
9.
10.

[Breast cancer chemoprevention (tamoxifen, raloxifene, and others)].

Funahashi H.

Nihon Rinsho. 2000 Apr;58 Suppl:587-91. Review. Japanese. No abstract available.

PMID:
11026055
11.

Tamoxifen and raloxifene may benefit women at high risk for breast cancer.

Rollins G.

Rep Med Guidel Outcomes Res. 2002 Jul 26;13(14):1-2, 5. No abstract available.

PMID:
12518771
12.

Raloxifene works as well as tamoxifen in preventing invasive breast cancer.

[No authors listed]

Mayo Clin Womens Healthsource. 2006 Oct;10(10):3. No abstract available.

PMID:
16977270
13.

The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.

Martino S, Costantino J, McNabb M, Mershon J, Bryant K, Powles T, Secrest RJ.

Oncologist. 2004;9(2):116-25. Review.

14.

Raloxifene and endometrial cancer.

Sismondi P, Biglia N, Ujcic E, Ponzone R, Roagna R.

Tumori. 2001 Sep-Oct;87(5):S18-9. No abstract available.

PMID:
11765199
15.

Chemoprevention of breast cancer.

Zelnak AB, O'Regan RM.

Curr Probl Cancer. 2004 Jul-Aug;28(4):201-17. Review. No abstract available.

PMID:
15318323
16.

The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N.

Clin Breast Cancer. 2002 Jun;3(2):153-9.

PMID:
12123540
17.
18.

From adjuvant therapy to breast cancer prevention: BCPT and STAR.

Dunn BK, Ford LG.

Breast J. 2001 May-Jun;7(3):144-57. Review.

PMID:
11469927
19.

A reconsideration of tamoxifen use for breast cancer.

Wang PH, Chao HT.

Taiwan J Obstet Gynecol. 2007 Jun;46(2):93-5. No abstract available.

20.

Selective oestrogen receptor modulation: molecular pharmacology for the millennium.

Levenson AS, Jordan VC.

Eur J Cancer. 1999 Dec;35(14):1974-85. Review.

PMID:
10711240

Supplemental Content

Support Center